Clinical Research Development Ireland (CRDI) is a not-for-profit research partnership comprising NUI Galway, Royal College of Surgeons in Ireland, Trinity College Dublin, University College Cork and University College Dublin, their medical schools, associated academic hospitals and clinical research facilities, with the objective of accelerating the translation of biomedical research into improved diagnostics, therapies and devices for patients. CRDI builds on the achievements of Molecular Medicine Ireland which was established in 2008 by the five aforementioned universities, together with its predecessor the Dublin Molecular Medicine Centre (DMMC), a partnership initiated by UCD and Trinity College Dublin in 2002, with the inclusion of Royal College of Surgeons in Ireland in 2005.

See CRDI Strategy 2017-2021 here »

Since 2002, CRDI and its partner institutions have succeeded in winning funding from Enterprise Ireland, EU FP6 & 7, Higher Education Authority PRTLI Cycles 1-5, Health Research Board, Health Service Executive, Irish Cancer Society/Movember, Science Foundation Ireland and the Wellcome Trust, for cross-institutional initiatives, such as, the Clinician Scientist Fellowship Programme and Clinical and Translational Research Scholars PhD programmes, Irish Clinical Research Infrastructure Network, Dublin Centre for Clinical Research, iPROSPECT and IPCOR prostate cancer research programmes, HRB Clinical Research Co-ordination Ireland, CURAM (SFI Centre for Research in Medical Devices) and the Irish Clinical Academic Training (ICAT) programme.

Strategic Goals

  • Advance the development of a sophisticated, coordinated clinical and translational research partnership across our partner academic institutions, their medical schools and associated hospitals.
  • Develop and support clinical and translational research infrastructure and delivery.
  • Develop and support clinical trials delivery.
  • Develop and support education and training.
  • Develop capability across network partners and CRDI.
  • Advocate for adequate funding for the development of clinical and translational research.